ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO928

Non-Alcoholic Fatty Liver Disease (NAFLD) Diagnosed by Bioimpedance (BIA) and Heart Failure With Preserved Ejection Fraction (HFpEF) in CKD Stages 1-5 ND

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials

Authors

  • Cigarrán Guldris, Secundino, Nephrology Hospital Publico Da Mariña, Burela, Lugo, Spain
  • Lomban, Jose, Cardiology Hospital Publico Da Mariña, Burela, Lugo, Spain
  • Pérez Casares, Luis Enrique, Cardiology Hospital Publico Da Mariña, Burela, Lugo, Spain
  • Sanjurjo amado, Ana maria, Nephrology Hospital Publico Da Mariña, Burela, Lugo, Spain
  • Varela, Eva Piñeiro, Nephrology Hospital Publico Da Mariña, Burela, Lugo, Spain
  • Grela, Lucía, Renal Research Unit. Hospital Publico Da Mariña, Burela, Lugo, Spain
  • Latorre, Juan, Renal Research Unit. Hospital Publico Da Mariña, Burela, Lugo, Spain
  • Calvino, Jesus, Nephrology Hospital Lucus Augusti, Lugo, Lugo, Spain
Background

NAFLD,the hepatic outcome of metabolic abnormalities such as obesity, insulin resistance or T2DM and dyslipidemia,affects about 25% of the general population worldwide and is associated with an increased incidence of CVD,including impaired cardiac structure and function, endothelial dysfunction and early carotid atherosclerosis.A new tool derived from bioimpedance has emerged to identify NAFLD in the four stages based on the ratio of fat/muscle.The aim of this cross-sectional study is to assess the influence of NAFLD diagnosed by BIA compared to ultrasound in CKD pts with HFpEF.

Methods

219 pts were included with GFR 44.22 ±12.9 60 ml/min, UACR 4419,19± 941.25 mg/gr crea.26% women,Age mean 73.14±12.2 yo, 90.4% obese and 50.2% diabetic.BIA ( Maltron, London) was performed using the manufacturer software based on the fat/muscle ratio, and echocardiographic HF was performed to determine subclinical left ventricular (LV) systolic dysfunction was defined using values of absolute peak global longitudinal strain (GLS).Analytical tests performed to assess liver function, GFR-EPI and UACR. AGEs by autofluorescence were read by (DiagnOtics,Groningen,Netherland)), and vascular Age was obtained from the Koetsier equation.The concordance between BIA & Liver echography was established in 195 pts with correlation of 96% for healthy and 98% for NAFLD.Data wre processed with SPSS 27 .A "p value <0.05 was considered statistically significant.

Results

Prevalence of NAFLD was: healthy 9.6%, Grade 1 10.5%, Grade 2 11%, Grade 3 18.7%, Grade 4 50.2%.NAFLD had higher LV filling pressure (E/e’ ratio:11.37±.7.01vs10.8±3.9,p<0.001) and worse absolute GLS (-13.69±4.0.%vs-14.85±5.4.4%, p<0.001) than non-NAFLD.When adjusted for HF risk factors,diabetes,carotid atheromatous or body mass index,NAFLD remained associated with subclinical myocardial remodelling and dysfunction (P < 0.01).

Conclusion

NAFLD prevalence in CKD pts is 50% and is independently associated with subclinical myocardial remodelling and dysfunction. It provides further insight into a link between NAFLD and HF in CKD pts.BIA is a noninvasive, economic, non-observer tool and of easy use.

Funding

  • Government Support – Non-U.S.